Project Details		
Project Code	MRCNMH25Ex Fox	
Title	Artificial Intelligence-enhanced mobile Behavioural Activation therapy for DEmentia and Mild cognitive impairment (ALBADEM)	
Posoarch Thoma	Neuroscience & Mental Health	
Summany	Demontia affects around EE million people globally, often leading to	
Summary	depression and unhealthy behaviours like physical inactivity and social isolation. These issues can worsen cognitive decline and reduce quality of life for both patients and their caregivers. Behavioural Activation therapy can help alleviate depression by encouraging engagement in enjoyable and meaningful activities. However, implementing behavioural activation faces several challenges and is not straightforward. Our study will test whether artificial intelligence-assisted mobile behavioural activation can overcome these barriers and improve accessibility and effectiveness for people living with dementia or mild cognitive impairment and their caregivers, ultimately enhancing their quality of life.	
Description	In the UK, approximately 944,000 people live with dementia and struggle with everyday activities, depression and social isolation. Behavioural Activation (BA) interventions focus on purposeful activity scheduling tailored to individual needs, are associated with improvements in activities of daily living and quality of life for people living with dementia(PLWD) and those with mild cognitive impairment (MCI). A meta-analysis of BA approaches found significant benefits, including higher levels of daily functioning and improved caregiver-rated quality of life(doi: 10.1002/14651858.CD009125.pub3). Emerging evidence suggests similar benefits for general older population, with better independence and quality of life. Despite promising early evidence, research on dementia prevention has been limited by implementation failures, unrepresentative samples, small effect sizes, lack of tailored interventions and ineffective technology integration. This PhD project addresses these gaps by exploring the use of an Al-assisted mobile platform (Iona Mind) adapted for PLWD and MCI, utilizing BA. The Al will categorize BA activities into themes: Routine, Enjoyable, and Necessary, targeting key risk factors for dementia and MCI progression. This innovative approach aims to improve accessibility, effectiveness, and overall quality of life for PLWD and MCI and their informal caregivers. KEY RESEARCH QUESTION: Can a mobile Al-assisted Behavioural Activation intervention improve mental and physical health outcomes for PLWD and MCI and their caregivers? SPECIFIC OBJECTIVES: 1. Synthesize the existing literature on the role of BA in PLWD and MCI. 2. Co-adapt and optimize an Al-assisted BA Intervention. 3. Conduct a Pilot Study of the usability of the BA intervention and conduct an initial investigation of health outcomes. METHODS: The proposed approach to intervention development follows the Medical Research Council (MRC) guidance.	

Phase 1 (Months 1-6): Updated Evidence Synthesis
Updated literature review on the role of Behavioural Activation (BA) in
PLWD and MCI. A systematic search of PubMed and Web of Science will
be performed to identify studies published since Cochrane Database Syst
Rev. 2022;4:CD009125; (doi: 10.1002/14651858.CD009125.pub3).
Randomized controlled trials and cohort studies examining the effects of
BA on PLWD and MCI will be reviewed. The review will include studies
that assessed mental or physical health outcomes. If the data is
sufficiently homogeneous, mixed linear regression models will be used
to model the relative effectiveness of BA interventions. Data will be
pooled first for all studies and then stratified by participant group
(PLWDvs.MCI) and type of BA intervention. These results will inform
Phase 2.
Phase 2 (Months 4-18: Co-adapting and Optimizing the AI-Assisted BA
Intervention(DOI: 10.2196/52389)
We will co-adapt and optimize the AI-assisted BA intervention using
Experience-Based Co-Design (EBCD). This process involves collaboration
with PLWD and MCI, and their informal caregivers to tailor the existing
Iona Mind AI intervention.
EBCD Stage 1: Setting Up
We will recruit 5 people living with dementia, 5 individuals with MCI, 5
informal carers, and 10 practitioners with lived experience (PWLE)
through our partnerships with Join Dementia Research, TIDE, Dementia
UK, and the Alzheimer's Society. 90-minute filmed interviews of
participants to share their experiences and reflect on their key needs
and support.
EBCD Stage 2: Gathering PWLE Experiences
their resenances and potential modifications. They will also consider
how to implement these recourses within surrent care pathways
FBCD Stage 3: Gathering Patient/Informal Carer Experiences
PWID or MCI and informal carers will view Iona BA materials in filmed
interviews discuss their experiences and suggest modifications. They
will explore resource accessibility. IT ontions, and design features
EBCD Stage 4: Co-designing Events
Co-design will begin with separate focus groups for PWLE, informal
carers. PLWD, and individuals with MCI, followed by a joint focus group.
At these events, an overview of findings from Stage 2 and Stage 3
interviews will be presented alongside the film. A facilitated discussion
will follow, which will be audio recorded and documented with field
notes.
Data will be analyzed using open coding techniques to develop robust
thematic descriptions. Normalisation Process Theory will inform data
interpretation, facilitating a comparative analysis of practice issues for
participants that may inform adoption, implementation, and integration.
EBCD Stage 5: BA Content Adjustment
The Iona BA intervention content will be adjusted based on the findings
from the previous stages. These adaptations will inform the
development of training materials for PWLE. The student will work with
Iona Mind to make the necessary content and technical adaptations.
Phase 3 (Months 18-28): Pilot Study for Usability and Health Outcomes

	The adapted Iona app will be deployed for 6 months with a PWP, 5 PLWD, 5 with MCI, informal carers, and wider service staff (PWLE). Acceptability, usability, and utility will be measured using the MHealth App Usability Questionnaire (doi: 10.2196/11500). Additionally, the potential effects on mental and physical health outcomes and quality of life will be assessed. The	
	SIDECAR(https://www.bradford.ac.uk/dementia/research/current- projects/sidecar/) measure will be administered to evaluate quality of	
	life, and the CSRI will be used to explore basic costs.	
Supervisory Team		
Lead Supervisor		
Name	Professor Chris Fox	
Affiliation	Exeter	
College/Faculty	Health and Life Sciences	
Department/School	Medical School	
Email Address	Christopher.fox@exeter.ac.uk	
Co-Supervisor 1		
Name	Professor Paul Farrand	
Affiliation	Exeter	
College/Faculty	CEDAR	
Department/School	Psychology	
Co-Supervisor 2		
Name	Professor Elizabeth Coulthard	
Affiliation	Bristol	
College/Faculty	Neurology	
Department/School	Medical School	
Co-Supervisor 3		
Name	Professor David Llewellyn	
Affiliation	Exeter	
College/Faculty	Medical School	
Department/School	Depart of Health and Community Sciences	